Advertisement

Topics

Latest "PharmaVentures Limited" News Stories

14:39 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "PharmaVentures Limited" found in our extensive news archives from over 250 global news sources.

More Information about PharmaVentures Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PharmaVentures Limited for you to read. Along with our medical data and news we also list PharmaVentures Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmaVentures Limited Companies for you to search.

Showing "PharmaVentures Limited" News Articles 1–25 of 261

Relevant

PharmaVentures to Sell Former AstraZeneca Manufacturing Plant in UK

OXFORD, England, Feb. 25, 2019 /PRNewswire/ -- PharmaVentures Limited is pleased to announce that it has been appointed to sell a former AstraZeneca manufacturing site in Avonmouth, near Bristol, ...


Pfizer and Wyeth’s $68bn Deal

Is the Pfizer and Wyeth deal a good move? Does this provide opportunities for other big pharma in 2009? Tibor Papp and Kevin Bottomley of PharmaVentures answer these questions and more in this special edition of the PharmaVentures Business Review.

PharmaTelevision: The Story So Far

In an interview with Ann Salter, Fintan Walton, CEO, PharmaVentures, looks back at the successful creation of PharmaVentures Business Review and discusses its growth and development since its launch in May 2006. He highlights the aims and strategy surrounding the formation of PharmaTelevision and outlines his plans to expand and develop the concept in 2007, with the addition of new channels and ev...


Fintan Walton & Adrian Dawkes, PharmaVentures; Will 2014 be the breakthrough year?

In this programme Adrian Dawkes talks to Fintan Walton, CEO PharmaVentures, about the recent JP Morgan Healthcare conference and the year ahead for the pharmaceutical and biotec industry. They discuss the challenges for big pharma in the emerging markets and look at the growth in the CRO space in Australia

PharmaDeals Research: Outsourcing of Deal Making Analysis

In this special feature interview, Fintan Walton talks with John Wyatt, Head of Commercial Development at PharmaVentures, about PharmaVentures' new service - PharmaDeals Research. John explains that PharmaDeals Research was launched to complement PharmaDeals Agreements in response to frequent customer requests for help with their deal-related research. These requests, John explains, were frequentl...

PharmaVentures CEO, Fintan Walton discusses the impact on deal-making in Q3 2010.

In this interview, PharmaVentures CEO, Fintan Walton discusses the impact on deal-making in Q3 2010 with reporter Helen Wright at the PTV studios, in Oxford, U.K.

PharmaVentures Nigel Borshell discusses co-promotions with Helen Wright.

In this interview, PharmaVentures Nigel Borshell discusses co-promotions with reporter Helen Wright at the PTV studios, in Oxford, UK.

PharmaVentures Nikki Watkins discusses Oncology with Helen Wright.

In this interview, PharmaVentures Nikki Watkins discusses Oncology with reporter Helen Wright at the PTV studios, in Oxford, U.K.

Part 3: The future of biotechs M&As: The investors' perspective

Dr Fintan Walton, CEO of PharmaVentures, asked a panel of leading industry fund managers how they are tailoring funds to ensure maximum return and the future of biotech M&A. They discuss: · Benefits of the current investment strategies used and new models for M&A · Big pharma - how they use their cash in M&A and acquisition and licensing of products · At what stage ...

Part 2: The future of biotechs M&As: The investors' perspective

Dr Fintan Walton, CEO of PharmaVentures, asked a panel of leading industry fund managers how they are tailoring funds to ensure maximum return and the future of biotech M&A. They discuss: · Benefits of the current investment strategies used and new models for M&A · Big pharma - how they use their cash in M&A and acquisition and licensing of products · At what stage ...

Part 1: The future of biotechs M&As: The investors' perspective

Dr Fintan Walton, CEO of PharmaVentures, asked a panel of leading industry fund managers how they are tailoring funds to ensure maximum return and the future of biotech M&A. They discuss: · Benefits of the current investment strategies used and new models for M&A · Big pharma - how they use their cash in M&A and acquisition and licensing of products · At what stage ...

Avara to Divest API Mfg. Site

PharmaVentures retained to sell the former AstraZeneca manufacturing plant in UK

Volume & Value, PTV News: Mar 02, 2010

PharmaVentures analysis of the impact of the financial crisis on pharma-deals

InDex Pharmaceuticals: Exciting Licensing Opportunity

InDex Pharmaceuticals AB are one of a number of biotechnology companies to emerge from the renowned Karolinska Institute in Sweden. CEO, Svante Rasmuson and CSO Oliver von Stein discuss the companies approach to developing drugs using it’s DIMS (DNA immunomodulatory sequence) technology to address inflammatory bowel disease and other immune and inflammatory diseases such as asthma and COPD. Spea...

Speed Reader, PTV News: Feb 15, 2010

Genome sequencing as common as a routine check-up. PharmaVentures' Adrian Dawkes comments on the implications for drug development.[Feb 15, 13:20 GMT]

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Initial SDS Microarray – Assay Performance Results of the V&V head-to-head study for the ...

Genetic Technologies Limited Provides End of Year Update on the Test Development Program

MELBOURNE, Australia, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, provides today an update on its R&D program for the year. Excellent R&D progress in 2018, approaching commercialisation early in 2019 As announced t...

Aleafia Health Completes Strategic Investment in Australia’s CannaPacific Pty Limited

Global Expansion Underway with 10% Equity Investment in Licensed Cannabis Cultivator CannaPacific among Australia’s only Federally Licensed Cultivators with projected 108,000 sq. ft. Greenhouse TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia Health”) or the (“Company”) is announcing its global expansion with the closing o...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 9,230,770 ordinary shares at a price to the public of $6.50 per share. The net proceeds to the Company from this offering are expected to be approximately $56.1 mi...

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the offering will be offered by the Company. In addition, the Company intends to grant the underwriters a ...

Genetic Technologies Limited Announces New Biomedical Blockchain Joint Venture

MELBOURNE, Australia, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), via its subsidiary Gene Ventures Pty Ltd, is pleased to announce that it has entered into a joint venture with Blockshine Technology Corporation (BTC). The joint venture (JV) company, called Blockshine Health, will pursue and develop blockchain opportunities in the biome...

Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

JERSEY, Channel Islands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:00 a.m. EST at the Lotte New York Palace Hotel, in New York, NY. ...

Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference

JERSEY, Channel Islands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop, will present at the Jefferies 2018 London Healthcare Conference on Tuesday, November 14th, 2018 at 8:40 a.m. GMT (3:40 a.m. Eastern Time). A webcast of the presentation will be available online ...

Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

JERSEY, Channel Islands, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3rd, 2018 at 4:00 p.m. EDT at The InterContinental New York Barclay Hotel, in New York, NY.  ...

Quotient Limited Announces Receipt of Consents to Modifications to the Company’s Senior Secured Notes

JERSEY, Channel Islands, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the receipt of consents from the holders of its Senior Secured Notes (the Notes) to certain amendments (the Proposed Amendments) to the indenture governing the Notes (the Indenture).    Franz Walt, Quotient’s Chief Executive Offi...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks